Axsome Therapeutics Cash Flow Statement
NASDAQ: AXSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
168.35-1.73 (-1.02%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Axsome Therapeutics free cash flow
In fiscal 2025, Axsome Therapeutics generated -$93.4 million of operating cash flow and spent $480,000 on capital expenditures. That left free cash flow of -$93.9 million, a free-cash-flow margin of -14.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Axsome Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -183.17M | -287.22M | -239.24M | -187.13M | -130.40M | -102.90M | -68.35M | -30.97M | -28.94M | -27.20M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 503.00K | 532.00K | 459.00K | 263.00K | 76.00K | 23.86K | 37.33K | 48.94K | 42.56K | 20.48K |
| Stock-Based Compensation | 93.75M | 85.22M | 62.62M | 37.73M | 20.80M | 14.76M | 6.12M | 1.75M | 2.07M | 2.03M |
| Change in Working Capital | -99.58M | -15.12M | -63.20M | -13.57M | -355.00K | 2.56M | 7.26M | 251.79K | -645.72K | 2.19M |
| Operating Cash Flow | -93.41M | -128.41M | -145.08M | -116.51M | -108.23M | -78.46M | -46.38M | -30.05M | -26.47M | -21.28M |
| Capital Expenditures | -480.00K | -270.00K | -582.00K | -702.00K | -308.00K | -45.89K | -16.12K | -32.70K | -9.90K | -104.56K |
| Investing Cash Flow | -480.00K | -270.00K | -582.00K | -53.70M | -308.00K | -45.89K | -16.12K | -32.70K | -9.90K | -104.56K |
| Debt Issued | — | — | — | — | — | 50.00M | 20.00M | — | — | 10.00M |
| Debt Repaid | -331.99M | — | — | — | — | -21.66M | -7.24M | -3.33M | -277.78K | — |
| Financing Cash Flow | 101.47M | 57.84M | 331.01M | 284.58M | 11.13M | 42.41M | 252.39M | 10.03M | 23.88M | 9.97M |
| Net Change in Cash | 7.58M | -70.84M | 185.35M | 114.37M | -97.40M | -36.09M | 206.00M | -20.05M | -2.60M | -11.42M |
| Free Cash Flow | -93.89M | -128.68M | -145.66M | -117.21M | -108.53M | -78.50M | -46.39M | -30.09M | -26.48M | -21.39M |
This table shows 10 annual periods of Axsome Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AXSM's reporting calendar. What is a cash flow statement?